Mitsubishi Tanabe Pharma
As of the edition of 20 October 2026, Mitsubishi Tanabe Pharma runs 22 drugs, 22 of them marketed; it is on route A at 0 targets and on route B at 12 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Mitsubishi Tanabe Pharma was acquired in 2025.
- Mitsubishi Tanabe Pharma Corporation: acquired in 2025
Drugs by status
| Status | Count |
|---|---|
| Marketed | 22 |
| Total | 22 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fentanyl | none listed | 6 |
| Amoxicillin | none listed | 0 |
| Infliximab | Ended 2018 (orphan exclusivity) | 3 |
| Metronidazole | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Canagliflozin anhydrous | Ends 2029 (patent) | 2 |
| Alteplase | Ended 1999 (computed from the first US licence) | 0 |
| Azathioprine | none listed | 2 |
| Fingolimod | none listed | 9 |
| Valganciclovir | none listed | 0 |
| Telaprevir | none listed | 0 |
| Acyclovir | none listed | 0 |
| Bisoprolol | none listed | 2 |
| Edaravone | Ends 2029 (exclusivity) | 0 |
| Vadadustat | Ends 2034 (patent) | 4 |
| Valbenazine | Ends 2036 (patent) | 2 |
| Teneligliptin | none listed | 0 |
| Argatroban | none listed | 1 |
| Inebilizumab | Ends 2032 (computed from the first US licence) | 1 |
| Bepotastine | none listed | 2 |
| Pazufloxacin | none listed | 0 |
| Ranimustine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 12 targets.
All 12 rows on route A or B
In the product12 company-target rows on route A or B; 9 are not shown here, and no score is.
See all 12 targets where Mitsubishi Tanabe Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.